| Nov 20 |
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
|
| Nov 19 |
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
|
| Nov 19 |
Top 3 Health Care Stocks You'll Regret Missing In Q4
|
| Nov 18 |
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
|
| Nov 17 |
Silence Therapeutics Third Quarter 2024 Earnings: Misses Expectations
|
| Nov 14 |
Silence Therapeutics reports Q3 results
|
| Nov 14 |
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
|
| Nov 13 |
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
|
| Oct 31 |
Is Silence Therapeutics plc (SLN) a Promising Gene Editing Stock?
|
| Oct 28 |
We're Hopeful That Silence Therapeutics (NASDAQ:SLN) Will Use Its Cash Wisely
|
